Explainer-What Novo Nordisk's weight-loss pill approval means for company, patients [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
expand access to millions of patients and give the Danish company a much-needed fillip in the red-hot market. The first GLP-1 pill specifically for ?obesity, also branded as Wegovy, is a 25-mg oral formulation of semaglutide, the active ingredient in the blockbuster injectable version. Here's what we know about ?this development: HOW DOES THE PILL COMPARE TO INJECTABLE WEGOVY? A 64-week, late-stage study showed participants who took the 25 mg of oral semaglutide once daily lost an average of 16.6% of their body weight, ?compared with 2.7% for those on a placebo. The injectable version of Wegovy won FDA approval in 2021 after a late-stage trial showed the drug produced an average weight loss of 14.9% at 68 weeks. Semaglutide belongs to the popular GLP-1 class of drugs driving what analysts expect will become a $150 billion-a-year global obesity market by the next decade. Oral weight-loss drugs are not expected to fully replace injectables, but analysts estimate pills coul
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Novo beats Lilly to first FDA-approved GLP-1RA pill for obesity [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk's weight-loss challenge in five charts [Yahoo! Finance]Yahoo! Finance
- Novo's Wegovy pill to test demand from consumers with cash [Yahoo! Finance Canada]Yahoo! Finance Canada
- Novo's Wegovy pill to test demand from consumers with cash [Yahoo! Finance]Yahoo! Finance
- Jim Cramer Says Eli Lilly's GLP-1 Pill Is “Going to Revolutionize Everything” [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 10/30/25 - Beat
LLY
Sec Filings
- 12/16/25 - Form 4
- 12/16/25 - Form 4
- 12/16/25 - Form 4
- LLY's page on the SEC website